Chromocell Therapeutics Corporation (CHRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chromocell Therapeutics Corporation (CHRO) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-447.14K) by net assets ($-6.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Chromocell Therapeutics Corporation worth for the company's overall valuation and market capitalisation.
Chromocell Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Chromocell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Chromocell Therapeutics Corporation stock quote for real-time trading data and today's change.
Chromocell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chromocell Therapeutics Corporation ranked by their cash flow conversion efficiency. Review CHRO financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GEN Restaurant Group, Inc. Class A Common Stock
NASDAQ:GENK
|
-0.201x |
|
Vessel Co. Ltd
KQ:177350
|
-0.055x |
|
Vitura Health Ltd
AU:VIT
|
-0.030x |
|
Ensysce Biosciences Inc
NASDAQ:ENSC
|
1.767x |
|
Weha Transportasi Indonesia TBK
JK:WEHA
|
0.069x |
|
Jwwinvest
WAR:JWW
|
0.098x |
|
OPTHEA LTD
F:UKJ
|
N/A |
|
Mydas Real Estate Investments Ltd
TA:MYDS
|
-0.280x |
Annual Cash Flow Conversion Efficiency for Chromocell Therapeutics Corporation (2020–2024)
The table below shows the annual cash flow conversion efficiency of Chromocell Therapeutics Corporation from 2020 to 2024. Also see CHRO current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | 0.00% |
| 2023-09-30 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | 0.00% |
| 2022-09-30 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | 0.00% |
| 2021-09-30 | $-3.68 Million | $-1.59 Million | 0.433x | -57.29% |
| 2020-12-31 | $-3.58 Million | $-3.63 Million | 1.013x | 0.00% |
| 2020-09-30 | $-3.58 Million | $-3.63 Million | 1.013x | -- |
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and id… Read more